Hosted on MSN

FDA approves Edwards’ TAVR system for asymptomatic aortic stenosis patients

The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...
Business Wire

Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
FierceBiotech

Edwards Lifesciences nets FDA approval opening up TAVR to patients before they show symptoms

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve implants to patients before they begin to show cardiac symptoms. The company ...
Business Wire

Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...